Home › Policy by country › Gender care in the United Kingdom
Gender care in the United Kingdom
The United Kingdom is the first major Western health system to openly distance itself from the gender-affirmative model for minors. On the basis of the Cass Review, NHS England closed the Tavistock clinic GIDS in 2023, permanently banned puberty blockers outside research settings, and restructured the entire care chain for young people with gender dysphoria. The British trajectory now forms the international reference point for an evidence-based reorientation.
Tavistock and the fall of GIDS
The Gender Identity Development Service (GIDS), based at the Tavistock and Portman NHS Foundation Trust in London, was for almost thirty years the only NHS centre for gender care for minors in England and Wales. In the 2010s the number of referrals shot up — from a few dozen to over 5,000 a year — with a striking over-representation of adolescent girls and young people with autism or co-morbid psychological problems.
From 2018 onwards clinicians came forward one after another with serious concerns: psychotherapist David Bell (Tavistock governor), psychologists Anna Hutchinson and Marcus Evans, and clinical advisor Sue Evans. They described a culture in which the gender-affirmative approach was hastily applied, co-morbidity was ignored, and critical questions were discouraged internally. In 2022 the Care Quality Commission rated GIDS as "inadequate". NHS England then decided to close it. The clinic was definitively closed in March 2024.
Bell v. Tavistock
The case of Bell v. Tavistock (2020) was a turning point in the British debate. Detransitioner Keira Bell, who as a teenager received puberty blockers and cross-sex hormones through GIDS and later underwent a mastectomy, brought a case against Tavistock. The High Court ruled that minors are almost never able to fully oversee the consequences of puberty suppression and therefore cannot give "Gillick-competent" consent. On appeal the ruling was reversed on procedural grounds, but the case strengthened the call for independent investigation — which ultimately led to the Cass Review. Bell herself became a prominent voice in the debate on detransition.
The Cass Review and the NHS turn
In 2020 NHS England commissioned an independent review led by paediatrician Dr Hilary Cass. The final report (April 2024) concluded, on the basis of systematic literature reviews by the University of York, that the evidence base for puberty suppression and cross-sex hormones in minors is "remarkably weak". NHS England accepted the recommendations in full and published its official response. An extensive discussion is on the Cass Review page.
Ban on puberty blockers
The British government announced that the ban on puberty blockers for clinical use in minors with gender dysphoria will be permanent — see the UK government announcement. The decision is based on advice from the Commission on Human Medicines and the Cass Review. Prescriptions are only permitted within a strict clinical research protocol (PATHWAYS study). Private clinics and online providers are no longer allowed to supply puberty blockers to minors either. The ban applies to new patients as well as to existing patients who had not yet started treatment.
New regional centres
Instead of one specialised clinic, NHS England now works with regional centres that apply a holistic approach: mental health care is paramount, not medical transition. Co-morbid problems — autism spectrum, trauma, eating disorders, depression — are systematically investigated before a gender diagnosis is made. Cross-sex hormones under 16 are not available; between 16 and 18 only under "extreme caution" and with extensive multidisciplinary assessment.
WPATH Files and British involvement
In March 2024 the WPATH Files appeared: leaked internal documents of the World Professional Association for Transgender Health showing that WPATH suppressed its own systematic reviews at Johns Hopkins when the outcomes were unwelcome. British researchers, including Cass herself, have publicly pointed to this as proof that the international guidelines on which the original English policy rested were not produced independently.
Situation in Scotland, Wales and Northern Ireland
The NHS is decentralised. Scotland (NHS Scotland) brought the Sandyford clinic largely into line with the Cass recommendations in 2024 and paused new prescriptions of puberty blockers. Wales follows the English policy. Northern Ireland had long referred patients to GIDS and has thereby automatically taken on the NHS England turn.
Sex change and legislation
Separate from medical care, the UK has the Gender Recognition Act 2004 for legal sex change. An attempt by the Scottish government to introduce self-identification was blocked by the UK government in 2023 with reference to consequences for sex-based rights. The UK Supreme Court ruled in April 2025 that "woman" in the Equality Act refers to biological sex — a ruling with major consequences for sport, shelters and prisons.